drugset / Trial / NCT04439578
Effect of Rifampicin on the Pharmacokinetics of SHR6390 in Healthy Subjects
NaSingle-groupOpen-labelBasic science
Summary
The primary objective of the study is to evaluate the effect of rifampicin on pharmacokinetics of healthy Chinese adult subjects after oral administration of SHR6390 tablets. The secondary objective of the study is to evaluate the safety of SHR6390 alone and when co-administered with rifampicin.
Timeline
- Start
- 2020-06-23
- Primary completion
- 2020-08-17
- Completion
- 2021-01-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Dalpiciclib | Small molecule | — | Oral |
| Subject | Rifampin | Small molecule | 600 mg | Oral |
Indications
No indication recorded.